Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-01-24

Clinical Trial Update: Phase IIIB Subcutaneous Abatacept Monotherapy Study [Phase 3]

View source ↗

Summary

A Phase III trial of subcutaneous abatacept monotherapy in rheumatoid arthritis completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ORENCIA (ABATACEPT)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Rheumatoid Arthritis (RA) | Phase 3 | Status: COMPLETED | Results posted: 2011-01-24